Okay, let's tackle this question about point mutations in proto-oncogenes and their role in gastrointestinal stromal tumors (GISTs). First, I need to recall which proto-oncogenes are commonly involved in GISTs. From what I remember, GISTs are typically associated with mutations in the KIT gene or the PDGFRA gene. These are receptor tyrosine kinases, right?

So, the question is asking which specific proto-oncogene has a point mutation leading to GIST development. The correct answer is probably KIT. Let me verify. KIT encodes the CD117 receptor, and activating mutations here lead to constitutive activation of the tyrosine kinase, promoting cell proliferation and survival. PDGFRA is another possibility, but I think KIT mutations are more common in GISTs.

Now, the options are A to D, but they're not listed here. Wait, the user provided the correct answer as "C. KIT" but the options are missing. Hmm, maybe they omitted the options. Let's assume the options include KIT, PDGFRA, others like RAS or BRAF. The other options would be incorrect because RAS or BRAF mutations are more associated with other cancers, like colorectal or melanoma. PDGFRA is less common than KIT in GISTs.

Wait, PDGFRA mutations can occur, but they are less frequent. So the main answer here is KIT. The point mutation leads to activation of the tyrosine kinase pathway, driving tumor growth. The clinical pearl here is that GISTs are the most common sarcomas of the GI tract and are driven by KIT or PDGFRA mutations. Targeted therapy with imatinib, which inhibits these kinases, is a standard treatment.

For the wrong options, if they included RAS or BRAF, those are involved in other cancers. If there's an option like TP53, that's a tumor suppressor, not a proto-oncogene. So each incorrect option should be explained why it's not linked to GISTs.

Putting this all together, the core concept is that GISTs are driven by mutations in KIT or PDGFRA proto-oncogenes, with KIT being the most common. The explanation should highlight the mechanism of constitutive activation due to point mutations, leading to uncontrolled cell division. The clinical pearl would emphasize KIT as the primary target and the role of imatinib.

**Core Concept**
Gastrointestinal stromal tumors (GISTs) are primarily driven by activating mutations in the **KIT** (CD117) or **PDGFRA** (platelet-derived growth factor receptor alpha) proto-oncogenes. These mutations cause constitutive activation of tyrosine kinase receptors, promoting uncontrolled cell proliferation and tumor formation. KIT mutations are present in ~80% of cases, while PDGFRA mutations account for ~5–10%.

**Why the Correct Answer is Right**
KIT encodes a transmembrane tyrosine kinase receptor. Point mutations in KIT (e.g., exon 11) lead to ligand-independent activation of downstream signaling pathways like MAPK/ERK and PI3K/AKT. This results in unchecked growth and survival of interstitial cells of Caj

✓ Correct Answer: A. KIT